Despite substantial dangers associated with Zelnorm, the FDA announced Friday that they will allow limited sales for those who are in “critical” need of the IBS drug.  Strict restrictions will be placed on who can receive Zelnorm, and it will remain unavailable for the general population due to an increased… Read more.

Following a Zelnorm recall in the United States on March 30 2007, Swiss pharmaceutical regulators announced last week that they have ordered the manufacturer, Novartis AG, to remove the foreign equivalent, Zelmac, from the market.  Swissmedic, the country’s regulatory agency, determined that the risk of heart attacks, strokes and angina… Read more.

Zelnorm was recently removed from the market after research linked the drug to an increased risk of heart attacks, strokes and other cardiovascular events.  Some individuals with constipation predominant IBS (irritable bowel syndrome) have been seeking Zelnorm alternatives to relieve their symptoms. >>INFORMATION: Zelnorm Recall

It has been one month since the Zelnorm recall was announced after the FDA determined that the IBS medication could increase the risk of cardiovascular events for users.  The lawyers at Saiontz & Kirk, P.A. have been contacted by hundreds of people concerned about injuries caused by the medication, and… Read more.

Zelnorm (generic tegaserod maleate) has been linked to an increased risk of heart attacks, strokes and other potentially life-threatening injuries.  Last week the FDA requested that the Novartis Pharmaceutical Corporation halt sales of the drug for treatment of irritable bowel syndrome since the dangers associated with the medication outweigh the… Read more.